Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy

Journal of Surgical Oncology

Volumn 104, Issue 1, 2011, Pages 10-16

  Marsman, H A ^a   Van Der Pool, A E ^b   Verheij, J ^b   Padmos, J ^c   Ten Kate, F J W ^a   Dwarkasing, R S ^b   Van Gulik, T M ^a   Ijzermans, J N M ^b   Verhoef, C ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Hepatic steatosis; Neoadjuvant chemotherapy; Non invasive detection

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; FATTY LIVER; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79958121084     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21874     Document Type: Article

References (30)

1. Fernandez FG, Drebin JA, Linehan DC, et al.: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-447.
2. Pawlik TM, Scoggins CR, Zorzi D, et al.: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-722 (discussion).
3. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. (Pubitemid 30644117)
4. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047. (Pubitemid 30162806)
5. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007-1016. (Pubitemid 351392040)
6. Tabernero J, Van CE, az-Rubio E, et al.: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-5232. (Pubitemid 350232254)
7. Kopetz S, Vauthey JN: Perioperative chemotherapy for resectable hepatic metastases. Lancet 2008;371:963-965. (Pubitemid 351389517)
8. Zorzi D, Laurent A, Pawlik TM, et al.: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94:274-286. (Pubitemid 46423843)
9. Rubbia-Brandt L, Audard V, Sartoretti P, et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-466. (Pubitemid 38444550)
10. Karoui M, Penna C, min-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7. (Pubitemid 43054046)
11. Nakano H, Oussoultzoglou E, Rosso E, et al.: Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008;247:118-124.
12. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072. (Pubitemid 46622116)
13. Vetelainen R, van Vliet A, Gouma DJ, et al.: Steatosis as a risk factor in liver surgery. Ann Surg 2007;245:20-30. (Pubitemid 46035431)
14. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
15. Behrns KE, Tsiotos GG, DeSouza NF, et al.: Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-298. (Pubitemid 128409616)
16. Kooby DA, Fong Y, Suriawinata A, et al.: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034-1044. (Pubitemid 37524071)
17. Brown RS Jr., Russo MW, Lai M, et al.: A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003;348:818-825. (Pubitemid 36245759)
18. Ratziu V, Charlotte F, Heurtier A, et al.: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906. (Pubitemid 40824701)
19. Qayyum A, Goh JS, Kakar S, et al.: Accuracy of liver fat quantification at MR imaging: Comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques - initial experience. Radiology 2005;237:507-511. (Pubitemid 41507887)
20. Kodama Y, Ng CS, Wu TT, et al.: Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol 2007;188:1307-1312. (Pubitemid 46668513)
21. Cho CS, Curran S, Schwartz LH, et al.: Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg 2008;206:480-488. (Pubitemid 351282515)
22. Limanond P, Raman SS, Lassman C, et al.: Macrovesicular hepatic steatosis in living related liver donors: Correlation between CT and histologic findings. Radiology 2004;230:276-280. (Pubitemid 37549813)
23. Park SH, Kim PN, Kim KW, et al.: Macrovesicular hepatic steatosis in living liver donors: Use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-112.
24. Bahl M, Qayyum A, Westphalen AC, et al.: Liver steatosis: Investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. Radiology 2008;249:160-166.
25. Kleiner DE, Brunt EM, van Natta M, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321. (Pubitemid 40770284)
26. Clavien PA, Petrowsky H, DeOliveira ML, et al.: Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545-1559. (Pubitemid 46588419)
27. Saadeh S, Younossi ZM, Remer EM, et al.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750. (Pubitemid 34977081)
28. Yoshimitsu K, Kuroda Y, Nakamuta M, et al.: Noninvasive estimation of hepatic steatosis using plain CT vs. chemical-shift MR imaging: Significance for living donors. J Magn Reson Imaging 2008;28:678-684.
29. Budny T, Palmes D, Stratmann U, et al.: Morphologic features in the regenerating liver - a comparative intravital, lightmicroscopical and ultrastructural analysis with focus on hepatic stellate cells. Virchows Arch 2007;451:781-791. (Pubitemid 47497943)
30. Newberry EP, Kennedy SM, Xie Y, et al.: Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology 2008;48:1097-1105.